Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
- Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
March 7, 2024
- Eisai Pledges Up to US$15 Million for Alzheimer’s Blood Test Player
March 7, 2024
- Takeda Triples Entyvio Production Capacity at Japan Site
March 7, 2024
- Sumitomo Pharma to Ax 400 US Jobs as it Rejigs North American Biz
March 7, 2024
- Ono Bags Cancer Drug License from South Korea’s NEX-I
March 7, 2024
- Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
- Shionogi/Nagasaki University Enter New Phase of Malaria Collab, Aim for Clinical Trials
March 6, 2024
- Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
- Mitsubishi, Daiichi Sankyo to Wind Up Diabetes Collab
March 6, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Shionogi, FunPep Enter Option Deal for Pollen Allergy Vaccine
March 6, 2024
- Astellas Kicks Off Japan PIII Studies for Hot Flash Med
March 5, 2024
- EU Regulators Accept Daiichi Sankyo’s TROP2 ADC for Review in Lung, Breast Cancers
March 5, 2024
- Shionogi, Osaka University Set Up Joint Research Lab on Long COVID
March 4, 2024
- Shionogi Healthcare Launches OTC Version of Mucodyne
March 4, 2024
- Taiho Picks Up Rights to China Pharma’s Lung Cancer Drug
March 4, 2024
- Moderna Japan Taps Kazumasa Nagayama as New President
March 4, 2024
- Drugstore Chains Tsuruha and Welcia to Merge, Eye Definite Pact by 2027-End
March 1, 2024
- FoundationOne Approved as CDx for Retevmo in Japan: Chugai
March 1, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…